Business Wire

CA-ANDERSEN-GLOBAL

26.8.2020 13:09:04 CEST | Business Wire | Pressemeddelelse

Del
Andersen forener sin latinamerikanske platform

De latinamerikanske medlemsfirmaer i Andersen Global vil nu operere under navnet ”Andersen”, hvilket styrker organisationens position som en one-stop-shop for skattemæssige og juridiske tjenester globalt. Meddelelsen kommer mindre end to måneder efter, at de europæiske medlemsfirmaer i Andersen Global antog Andersen-navnet.

Andersen Globals medlemsfirmaer i Brasilien, Ecuador, Guatemala, Mexico og Uruguay, der tidligere opererede under navnene, ”Andersen Tax” og ”Andersen Tax & Legal,” har nu Andersen som deres navn sammen med de nye medlemsfirmaer, MODO Law og GSRC i Argentina, der blev medlemsfirmaer i organisationen tidligere på året.

Andersen Global fortsætter med at betragte udvidelse af både sit fodaftryk i Latinamerika og sin nyetablerede platform i Caribien som høje prioriteter. I Latinamerika har den globale organisation også en tilstedeværelse i Chile, Colombia, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Paraguay og Peru gennem sine samarbejdsfirmaer, og har tilføjet samarbejdsfirmaer i 11 lande i Caribien i løbet af de sidste seks måneder.

”Vores ekspansion er drevet af kundeservice, og vores målsætning er ikke at være det største firma, snarere handler vores fokus om vores engagement i at opbygge et firma, hvor kunder får uovertrufne skattemæssige og juridiske tjenester på en sømløs måde overalt i verden,” sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. ”Vores organisation er ikke kun dedikeret til vores kunder, men også til at investere i vores medarbejdere og den næste generation. Vi deler alle de samme værdier og den samme vision uanset grænser, og det er kun passende, at dette også afspejles i vores navn.”

Organisationens rejse begyndte i 2002, da 23 tidligere Arthur Andersen-partnere oprettede skattefirmaet WTAS. I 2014 antog det amerikanske medlemsfirma navnet “Andersen Tax” og overgik for nylig til Andersen-navnet i 2019. Den globale organisation er vokset eksponentielt siden etableringen af Andersen Global (tidligere WTAS Global) af det grundlæggende amerikanske medlem Andersen Tax LLC i 2013. Efter lanceringen af sin globale platform i Europa debuterede Andersen Global i Latinamerika i 2015. Regionen er siden vokset til mere end 34 lokaliteter, 1.000 skatte- og juraeksperter, og 90 partnere i dag.

Leonardo Mesquita, regional administrerende direktør for Latinamerika tilføjede, ”Vores organisations fundament er baseret på vores fælles vision om at forblive uafhængige og levere sømløse, synergistiske tjenester til vores kunder globalt. Vi glæder os til at have et navn, der afspejler det, vi allerede ved – vi er ét firma.”

I løbet af det næste år fortsætter medlemsfirmaer globalt med at antage Andersen-navnet, mens Andersen Global fortsætter sin ekspansionsindsats på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.

Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 191 lokaliteter via sine medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye